BSX Stock - Boston Scientific Corporation
Unlock GoAI Insights for BSX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B |
| Gross Profit | $10.27B | $8.83B | $7.71B | $7.46B | $5.58B |
| Gross Margin | 61.3% | 62.0% | 60.8% | 62.8% | 56.2% |
| Operating Income | $2.63B | $2.18B | $1.82B | $1.92B | $601.00M |
| Net Income | $1.85B | $1.59B | $698.00M | $1.04B | $-82,000,000 |
| Net Margin | 11.1% | 11.2% | 5.5% | 8.7% | -0.8% |
| EPS | $1.26 | $1.08 | $0.45 | $0.69 | $-0.08 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 3rd 2025 | Erste Group | Downgrade | Hold | - |
| September 8th 2025 | Oppenheimer | Upgrade | Outperform | $125 |
| June 16th 2025 | Leerink Partners | Initiation | Outperform | $118 |
| April 16th 2025 | Needham | Upgrade | Buy | $113 |
| January 10th 2025 | Deutsche Bank | Upgrade | Buy | $108 |
| October 18th 2024 | Needham | Downgrade | Hold | - |
| May 30th 2024 | Goldman | Initiation | Buy | $90 |
| February 1st 2024 | Mizuho | Upgrade | Buy | $80← $65 |
| July 19th 2023 | Robert W. Baird | Initiation | Outperform | $59 |
| June 30th 2023 | CL King | Initiation | Buy | $64 |
| May 30th 2023 | Morgan Stanley | Resumed | Overweight | $58 |
| March 29th 2023 | UBS | Initiation | Buy | $57 |
| December 22nd 2022 | Mizuho | Initiation | Neutral | $52 |
| December 20th 2022 | Citigroup | Resumed | Buy | $54 |
| October 18th 2022 | Barclays | Initiation | Overweight | $49 |
Earnings History & Surprises
BSXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.78 | — | — | — |
Q4 2025 | Oct 22, 2025 | $0.71 | $0.75 | +5.0% | ✓ BEAT |
Q3 2025 | Jul 23, 2025 | $0.72 | $0.75 | +3.4% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $0.67 | $0.75 | +11.4% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $0.66 | $0.70 | +6.5% | ✓ BEAT |
Q4 2024 | Oct 23, 2024 | $0.59 | $0.63 | +7.1% | ✓ BEAT |
Q3 2024 | Jul 24, 2024 | $0.58 | $0.62 | +6.3% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.51 | $0.56 | +8.9% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $0.51 | $0.55 | +7.8% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.48 | $0.50 | +4.2% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.49 | $0.53 | +8.2% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.43 | $0.47 | +9.3% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $0.47 | $0.45 | -4.3% | ✗ MISS |
Q4 2022 | Oct 26, 2022 | $0.44 | $0.43 | -2.3% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $0.42 | $0.44 | +4.8% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $0.38 | $0.39 | +2.6% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $0.44 | $0.45 | +2.3% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.40 | $0.41 | +2.5% | ✓ BEAT |
Q3 2021 | Jul 27, 2021 | $0.37 | $0.40 | +8.1% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $120
📈 PositiveCanaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $131
➖ NeutralRBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $130
📈 PositiveBTIG Reiterates Buy on Boston Scientific, Maintains $132 Price Target
📈 PositiveTruist Securities Maintains Buy on Boston Scientific, Raises Price Target to $130
📈 PositiveWells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $125
📈 PositiveMorgan Stanley Maintains Overweight on Boston Scientific, Raises Price Target to $130
📈 PositiveBTIG Reiterates Buy on Boston Scientific, Maintains $132 Price Target
📈 PositiveBoston Scientific shares are trading higher after the company reported Q3 EPS and sales above expectations and raised its FY2025 adjusted EPS guidance.
📈 PositiveBoston Scientific Raises FY2025 GAAP EPS Guidance from $1.89-$1.93 to $1.97-$2.01 vs $1.98 Est
📈 PositiveBoston Scientific Sees Q4 GAAP EPS $0.48-$0.52 vs $0.52 Est
📉 NegativeBoston Scientific Sees Q4 2025 Adj EPS $0.77-$0.79 vs $0.76 Est; Sees Sales $5.220B-$5.310B vs $5.178B Est
📈 PositiveBoston Scientific Raises FY2025 Adj EPS Guidance from $2.95-$2.99 to $3.02-$3.04 vs $2.98 Est; FY2025 Revenue expected to be around $20.100B vs $19.875B Est
📈 PositiveBoston Scientific Non-GAAP EPS of $0.75 beats by $0.04, revenue of $5.07B beats by $100M
📈 PositiveBoston Scientific Q3 2025 Adj. EPS $0.75 Beats $0.71 Estimate, Sales $5.065B Beat $4.967B Estimate
📈 PositiveNeedham Reiterates Buy on Boston Scientific, Maintains $121 Price Target
📈 PositiveBoston Scientific To Acquire Nalu Medical For ~$533M, Expanding Neuromodulation Portfolio For Chronic Pain; Closing Expected In H1 2026
📈 PositiveEvercore ISI Group Maintains Outperform on Boston Scientific, Lowers Price Target to $110
➖ NeutralBarclays Maintains Overweight on Boston Scientific, Raises Price Target to $136
📈 PositiveTruist Securities Maintains Buy on Boston Scientific, Raises Price Target to $129
📈 PositiveFrequently Asked Questions about BSX
What is BSX's current stock price?
What is the analyst price target for BSX?
What sector is Boston Scientific Corporation in?
What is BSX's market cap?
Does BSX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BSX for comparison